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Abstract 
 Alzheimer’s Disease (AD) is a form of age-related neurodegeneration that 
occurs sporadically and affects 5.4 million individuals in the United States alone.  
Individuals with Down Syndrome (DS) develop the neuropathology of AD, 
suggesting the overexpression of genes on chromosome 21, like Regulator of 
Calcineurin1 (RCAN1), play a role in AD.  RCAN1 is under the control of a stress-
response promoter, but it is unknown whether chronic stress (CS) causes an 
elevation in RCAN1 levels.  Here we show a mild CS paradigm is successful at 
promoting increased anxiety and elevating stress hormone levels, through 
behavioral tests and glucocorticoid analysis.  This is a first step in looking at CS and 
RCAN1 expression.  Based on these findings we propose to test the idea CS causes 
elevated glucocorticoid levels and induces RCAN1 expression in the brain to 
increase.  
 
Introduction 
Alzheimer’s Disease (AD) is the most prevalent form of age-related 
neurodegeneration.  Causes of AD include environmental, genetic, and lifestyle 
related factors, but it is thought that less than 5 percent of AD is caused by specific 
genetic changes [1, 2].  The greatest identified risk for AD is aging.  However, most 
cases of AD occur sporadically, that is the underlying causal factors are unknown.  
AD causes brain cell degeneration and neuronal cell death, destroying 
memory and mental function in individuals who express the AD phenotype [1, 2].  
Individuals suffering from AD are susceptible to symptoms that often worsen as the 
disease progresses, including but not limited to: memory loss, difficulty thinking and 
concentrating, loss of communication abilities, changes in personality and behavior, 
reduced planning abilities, inability to do familiar tasks, decline of judgments and 
decision making skills, decreased spatial awareness, and loss of surrounding [1].   
Two brain abnormalities, considered histopathological hallmarks of severe 
AD, are Amyloid-Beta protein plaques (AB Plaques) and Tau protein tangles [1,2].  
AB Plaques interfere with synapses important for communication between cells, 
eventually destroying synapses in the brain [1,3].  Tau protein tangles made from 
hyperphosphorylated tau damage the microtubule transport system necessary for 
carrying nutrients and other materials between nerve cells, leading to cell death 
[1,4].  Both AB Plaques and Tau protein tangles are thought to contribute to 
cognitive function loss seen in AD.  Individuals with Down Syndrome (DS) display 
early onset of AD neuropathology and provide an opportunity to research genetic 
factors associated with AD.   
Regulator of Calcineurin1 (RCAN1) is a gene located on chromosome 21 that 
codes for a protein that interacts with calcineurin to inhibit calcineurin-dependent 
signaling [5].  DS is caused by trisomy 21, so RCAN1 is overexpressed in DS 
individuals and DS model mice, as well as individuals with sporadic AD, and the 
elderly[6,7].  RCAN1 accumulation has been linked to oxidative stress [8, 9, 10] and 
mitochondrial dysfunction [11, 12, 13], features of AD, as well as being linked to 
aging and AD itself [6, 10, 11].  Specifically, overexpression of RCAN1.1S, a protein 
isoform of RCAN1, has been shown to induce hyperphosphorylation of tau, 
aggregate formation, synapse irregularities, and apoptosis, all features of AD 
pathophysiology [14, 15, 16, 17].  A mouse model has been developed (RCAN1TG 
mice) that overexpress the RCAN1 isoform RCAN1.1S.  These mice have been shown 
to develop age-dependent cognitive and synaptic impairments, consistent with age-
dependent dementia in AD [10].  RCAN1 expression is controlled by a stress 
response promoter induced by chronic stress (CS).  Overexpression leads to RCAN1-
mediated neurodegeneration.   
It is hypothesized that RCAN1 overexpression due to CS contributes to AD 
pathophysiology, promoting cognitive deficits within the disease itself.  In order to 
test this, mice were exposed to a CS paradigm that mimics CS in humans.  Behavioral 
tests and glucocorticoid analysis were carried out to verify the CS paradigm was 
successful and mice displayed anxiogenic behavior.  Further research efforts will 
seek evidence of elevated RCAN1 levels in the brain.  
While there is no current cure for AD, identifying biomarkers such as RCAN1 
may facilitate early diagnosis and treatment of the disease.  It is currently unknown 
whether expression of RCAN1 alone is sufficient to drive brain alterations leading to 
an AD phenotype or leads to an increased pre-disposition to AD, however further 
research may determine a correlation, if any.  Research has been done at the 
University of Colorado, Boulder in the Molecular Signaling of Neurological Disorders 
Laboratory involving RCAN1 and its causative association with AD.  Research for 
this project has been developed from peer-reviewed research articles as well as 
unpublished data from the Hoeffer Lab. 
 
Methods 
IACUC protocol 1311.02 (January 2014-January 3, 2017) was used 
throughout the entire experiment.  C57 wild type (WT) mice aged 3-4 months were 
exposed to a CS paradigm designed to mimic chronic stress in humans [18, 19].  
Following CS, the following were assessed: (1) elevated plus maze and open field 
activity for stress-affected behaviors. These tests were used to assess mouse 
correlates of anxiety and depression, behaviors impacted by exposure to CS [20, 21].  
(2) Enzyme-linked immunosorbent assay (ELISA) for serum corticosterone levels 
were used for measurement of hypothalamic–pituitary–adrenal (HPA) axis 
activation.  HPA axis activation measures stress response hormonally and was used 
to corroborate behavioral tests [22].  Mice exposed to the CS paradigm were 
compared against age-/sex-matched littermates not exposed to the paradigm. 
Chronic Stress Paradigm 
CS treatment lasted 30 days, in which the mice were exposed to behavioral stressors 
including intermittent inescapable shock, predator odor, and forced restraint [20, 
21, 23].  These treatments were unpredictable and sporadic throughout the 30-day 
period. 
Mouse, open field analysis (OFA) standard procedures 
Animals to be tested were removed from their homeroom and brought to the 
behavioral testing area in home cages.  The mouse was placed in the center of a 
clear, Plexiglas chamber (43X43X18 cm).  A Plexiglas lid with 28 1-cm holes was put 
in place to cover the chamber. The animal remained in the chamber for 10 minutes 
to explore the novel environment.  A computer program, Noldus, monitored the 
exploration of the animal.  After 10 min, the animal was removed from the chamber 
and returned to its home cage. The Plexiglas chamber was wiped clean with ethanol 
and water in-between trials. After the mice were tested they were returned to their 
homeroom in their home cages [24].  
Mouse, elevated plus maze (EPM) standard procedures 
Animals to be tested were removed from their homeroom and brought to the 
behavioral testing area in home cages. The elevated plus maze consists of four 
runways (5 cm x 30 cm) arranged perpendicularly and elevated 38 cm off of the 
ground. 15.5 cm white metal walls enclose two arms while the other two arms 
remain open. The animal was placed in a bottomless start box in the center of the 
elevated maze. The start box was lifted, allowing the mouse to move into the opened 
or closed arms. The animal remained in the maze for 10 minutes. A computer 
program, Noldus, monitored the exploration of the animal. After 10 minutes the 
animal was lifted from the maze and returned to its home cage. The maze was wiped 
clean with ethanol and water in-between trials.  After the mice were tested they 
were returned to their homeroom in their home cages [24]. 
ELISA 
Collection 
Fecal samples were collected throughout the CS paradigm for analysis by Arbor 
Assays DetectX Corticosterone Enzyme Immunoassay Kit.  Fecal samples were 
collected twice a week and stored in the -80C freezer until ready for preparation.   
Sample Preparation 
Samples were weighed and 1mL of Ethanol was added for every 0.1gm of feces.  The 
maximum amount of ethanol used was 1mL.  Samples were shook vigorously in the 
cold room for 30 minutes, then centrifuged at 5,000 rpm for 15 minutes at 4C.  
Supernatant was transferred to clean tubes.  Supernatant was evaporated to 
dryness in a SpeedVac and dried extracted samples were stored in a desiccator in 
the -80C freezer.  When ready to run a plate, extracted samples were dissolved in 
100uL Ethanol and 400uL Assay Buffer (AB), vortexed and allowed to sit for 5 
minutes 3 times.  The ethanol content was brought to below 5% by diluting with AB 
[25].  
ELISA  
The DetectX Corticosterone Enzyme Immunoassay Kit quantitatively measures 
corticosterone present in fecal samples.  A standard curve was made from a 
provided corticosterone stock.  Standards and samples were pipetted into a clear 
micotiter plate coated with antibodies to capture sheep antibodies.  A 
corticosterone-peroxidase conjugate was added to wells.  A polyclonal antibody to 
corticosterone was added to the wells to initiate binding and allowed to incubate for 
1 hour.  The plate was then washed and substrate added to react with bound 
corticosterone peroxidase conjugate.  The reaction is then stopped and the intensity 
of color is read in a plate reader at 450nm.  The concentration of coritocosterone in 
the samples was calculated based off the standard curve, blanks, and controls [25].  
Data Analysis  
Simple comparisons between experimental and control mice in weight, EPM, OFA, 
and ELISA were done with two-tailed independent student t-tests.  Outliers were 
removed as necessary. 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
Weights 
Mice were weighed following conclusion of the CS paradigm and before behavior.  It 
was observed that over the course of behavior testing, CS mice had a trend of 
increasing weight.  No significance was found between differences in weight.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.  
Average weights of control (n=16) and CS (n=16).  An independent t-test was conducted to 
compare average weights of control mice and mice exposed to CS.  No significance was found.   
OFA 
To examine whether CS caused anxiety-related behaviors, OFA was carried out.  
Data showed CS mice spent significantly less time in the center, t(30)=2.75, 
p=0.0222, than controls, suggesting CS mice had more anxiety.  This result was 
confirmed by the significantly reduced total distance moved in CS mice, t(30)=2.75, 
p=0.0018, compared to controls.   
 
 
 
 
 
 
 
Figure 2. 
A) Time spent in zones during OFA testing for control (n=16) and CS (n=16).  An 
independent t-test was conducted to compare time spent in each zone for control 
mice and mice exposed to CS.  There was a significant difference in the time spent 
in the center zone, t(30)=2.75, p=0.0222, with stressed mice spending less time in 
the center zone.   
B) Total distance moved during OFA testing for control (n=16) and CS (n=16).  An 
independent t-test was conducted to compare total distance moved of control mice 
and mice exposed to CS.  There was a significant difference in the total distance 
moved t(30)=2.75, p=0.0018, with stressed mice moving less.  
EPM 
Behavior of mice was then tested in EPM.  Compared to controls, CS mice spent 
significantly reduced time in the open arms of the EPM, t(30)=2.042, p=0.0382, 
instead staying in the closed arms.  This is similar to OFA data.  Also consistent with 
OFA data, CS mice moved significantly less overall, t(30)=2.75, p=0.0033, compared 
to controls.  Time spent in closed arms of the EPM was near significant, p=0.065875, 
with CS mice spending more time in closed arms.  Combined with OFA results, EPM 
behavior of CS mice support CS causing anxiogenic behavior.   
 
 
 
 
Figure 3. 
A) Time spent in zones during EPM for control (n=16) and CS (n=16).  An independent t-
test was conducted to compare time spent in each zone for control mice and mice 
exposed to CS.  There was a significant difference in time spent in the open arm, 
t(30)=2.042, p=0.0382, with stressed mice spending less time in the open arm.   
B) Total distance moved during EPM testing for control (n=16) and CS (n=16)An 
independent t-test was conducted to compare total distance moved for control mice 
and mice exposed to CS.  There was a significant difference in total distance moved, 
t(30)=2.75, p=0.0033, with stressed mice moving less.  
ELISA 
ELISA was run to test glucocorticoid concentration.  Data show male CS mice had 
almost equal corticosterone concentrations 6 days into the CS paradigm compared 
to controls.  By day 17 of the paradigm, male CS mice have significantly higher 
corticosterone concentrations, t(30)=, p=0.0246, compared to controls.  Along with 
behavior data, ELISA results support the idea that the CS paradigm was successful, 
causing increased glucocorticoid levels and anxiogenic behavior in mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. 
Corticosterone concentrations of control (n=16) and CS (n=16) at day 6 and 17 of the CS paradigm in males 
and females, as well as combined sexes.  An independent t-test was conducted to compare corticosterone 
concentrations between control mice and mice exposed to CS on the same day of the CS paradigm.  There 
was a significant difference in corticosterone concentration in males on day 17, t(30)=, p=0.0246, with 
stressed males having higher corticosterone concentration.  
 
Discussion  
Following a 30-day CS paradigm, two behavioral tests measuring anxiety in rodents 
showed mice exposed to CS spent less time in exposed areas, indicative of increased 
anxiety.  Using ELISA to measure glucocorticoid levels, increased anxiety due to CS 
was used to confirm behavior results.   
CS Paradigm 
While we were fairly happy with the CS paradigm, it was observed in a previous 
cohort that mice repeatedly exposed to predator odor appeared to physically, 
though not physiologically, habituated to predator odor.  To combat this, mice were 
conditioned to the odorant using intermittent inescapable shock to heighten 
aversion to the odor.  One drop of predator odor was added during intermittent 
inescapable footshock.  During odorant stress, the mice will likely undergo 
extinction, then renewal during footshock experiments.  We hypothesize that this 
slight change to the paradigm resulted in a significantly more stressful experience 
for the experimental mice. 
Weights 
Based on data from a previous cohort of this experiment, it was hypothesized that 
the absence of CS allowed CS mice to normalize weights to control counterparts.  In 
a previous cohort CS mice were significantly smaller in weight than controls 
immediately after CS, and significance in weight differences declined as behavior 
was carried out, possibly due to the absence of CS.  Here we find no significant 
difference in weights between experimental conditions, but observe a trend that CS 
mice gain weight as behavior goes on, eventually reaching weights similar to 
controls.  Again, it is hypothesized that the absence of CS allows CS mice to 
normalize their weights, but a larger sample size is needed to confirm this trend in 
weights following the CS paradigm.   
OFA 
OFA data show mice exposed to the CS paradigm spent significantly less time in the 
center of the arena compared to controls and moved significantly less overall.  This 
is expected behavior because mice with increased anxiety freeze more frequently 
[27].  Together, these results are consistent with previous research showing CS 
causes increased anxiety in mice [20, 26].  
EPM 
EPM data show mice exposed to the CS paradigm spent significantly less time in 
open arms compared to controls.  Similar to OFA, this is consistent with previous 
research showing CS causes increased anxiogenic behavior [20, 26].  CS mice also 
moved significant less overall, compared to controls.  Again, more frequent freezing 
is expected in CS mice due to increased anxiety [27].  Time spent in the closed arms 
of the EPM by CS mice was almost significant compared to controls.  This is also 
expected as closed arms are a safer environment than open arms, and more 
frequent freezing is expected in mice exposed to the CS paradigm [27].  The number 
of crossings between zones was similar for CS and control groups, showing a 
locomotor deficit does not explain increased closed arm  time, but rather CS causes 
increased anxiety.  Additionally, when closed arm time and center time are 
combined, CS mice spend significantly more time in the closed arm+center, 
compared to controls.  The center area of the EPM is a kind of middle ground 
between the safe environment of the closed arms, and vulnerable environment of 
the open arms.  It is hypothesized that CS mice do not find the center as anxiety-
inducing as the open arms, and therefore spend more time there.  
ELISA 
We hypothesized that CS would increase glucocorticoid levels in both male and 
female CS mice, however our data does not fully support this.  While male CS had a 
significant change in corticosterone concentration over the course of the CS 
paradigm, female CS did not.  A possible explanation for why female CS mice did not 
have elevated glucocorticoid levels is they were not estrous cycling together and 
different hormone levels effected their glucocorticoid levels.  Although female mice 
were housed together, they were not together since birth, causing variation in 
estrous cycling.  In a previous study it was shown that estrogen, specifically 
estradiol, impairs the ability of dexamethasone (DEX) to inhibit the rise in 
corticosterone during the stress-induced rise in corticosterone, suggesting estradiol 
causes a disregulation of HPA axis negative feedback [28].  DEX is a synthetic 
glucocorticoid that acts competitively with natural corticosterone in non-human 
mammals [29].  Because female mice were not cycling together it is possible that 
estrogen levels varied across subjects, and inhibition of the rise in corticosterone 
was not occurring simultaneously, causing variation in corticosterone levels, unlike 
in male CS.  Research to find ways to get female mice to cycle together is underway, 
but implementing the task could be difficult.   
 
Future Direction 
Here it has been shown that the CS paradigm implemented was successful in 
causing increased anxiety in mice.  While glucocorticoid levels were only 
significantly increased in male CS, results from OFA and EPM support evidence of 
anxiogenic behavior in both male and female CS.  Whether this is through 
glucocorticoid signaling remains elusive, as only male CS mice showed significant 
changes in corticosterone levels throughout CS.  Further research will need to be 
done to confirm CS causes increases in glucocorticoid signaling in both male and 
female mice.   
Access to voluntary exercise is another condition that will be added to future 
cohorts to see if  it will have any effect on RCAN1 levels following CS.  Wheels in 
home cages will be attached to computer software to monitor the activity of the 
mice.  It is hypothesized that CS mice might use exercise as an outlet to combat the 
CS and cause smaller increases in RCAN1 levels. 
So far it is unknown whether RCAN1 levels were impacted by CS.  To answer 
this, brain protein from three experimental test groups (immediate, aged, old) will 
be isolated and western blotting will determine if RCAN1 isoform expression is 
increased in the brain following CS [24, 30].  If found to be correct, the hypothesis 
that CS increases RCAN1 levels via glucocorticoid signaling  will be confirmed.  If CS 
is shown to cause increases in RCAN1 expression, and accumulation of RCAN1 has 
been previously linked to AD neuropathology [8, 9, 10, 11, 12, 13],  this suggests 
individuals predisposed to AD should avoid chronic stress in order to keep RCAN1 
accumulation in the brain at healthy levels. 
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